4 results
To evaluate the safety and effectiveness of the OMGEA Coronary Stent System for the treatment of subjects with a de novo atherosclerotic coronary artery lesion * 28 mm in length (by visual estimate) in a native coronary artery *2.25 mm to *4.50 mm…
The objective of this prospective, observational study is to ensure the safety and the wellbeing of subjects treated with the NEVO* SES.
To characterize the safety, tolerability, and recommended phase 2 dose (RP2D) of each combination partner used with ruxolitinib (Part 1)To evaluate the preliminary efficacy of each novel ruxolitinib combination treatment arm (Parts 2 & 3)
The purpose of this study is to allow collection of safety and tolerability data in subjects benefitting from treatment with spartalizumab as a single agent or in combination with other study treatments in a pre-defined (Appendix Section 16.1)…